key: cord-0934709-1bdumn36
authors: Pang, Wentai; Liu, Zhi; Li, Nan; Li, Yuyun; Yang, Fengwen; Pang, Bo; Jin, Xinyao; Zheng, Wenke; Zhang, Junhua
title: Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis
date: 2020-07-28
journal: Integr Med Res
DOI: 10.1016/j.imr.2020.100477
sha: eb4b3bf90931706d44b0a97e41da46876e188f0d
doc_id: 934709
cord_uid: 1bdumn36

BACKGROUND: Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19. METHOD: A literature search was performed in six databases from injection to June 2020. Both randomized controlled trials (RCTs) and quasi-RCTs were considered as eligible. The quality of included RCTs were assessed by Cochrane Risk of Bias Tool, and Review Manager 5.3 software was used to do meta-analysis. RESULT: Eleven studies with 1259 patients were included in this study. CMD included herbal decoction and Chinese patent medicine. The methodological quality was evaluated as generally unclear. The results of meta-analysis showed that the integration of CMD and WM had better efficacy than WM in number of patients turned to severe and critical type (RR = 0.47, 95% CI=[0.32, 0.69], P < 0.0001), length of hospital stay (MD= -7.95, 95% CI=[-14.66, -1.24], P = 0.02), defervescence time (MD= -1.20, 95% CI=[-2.03, -0.38], P = 0.004), cough resolution rate (RR = 1.37, 95% CI=[1.15, 1.64], P = 0.0004), fatigue resolution rate (RR = 1.37, 95% CI=[1.02, 1.83], P = 0.04), and tachypnea resolution rate (RR = 2.20, 95% CI=[1.11, 4.39], P = 0.02). As for safety, there was no significant difference between two groups. CONCLUSION: CMD may bring potential benefit to patients suffered from COVID-19. However, the quality of included trials is not good enough. High quality study with core outcome set are still required.

coronavirus (2019-nCoV). [1] The pathogenesis of COVID-19 is similar to pneumonia induced by other viruses. Specifically, 2019-nCoV infection can cause systemic inflammation, fever, hypoxia, electrolyte imbalance, acid-base disturbance and even shock. [2, 3] Overaction of immune system lead to cytokine storm and excessive oxidative stress may be responsible for disease progression and even death. [4, 5] COVID-19 can be classified into mild, ordinary, severe and critical types based on disease severity. The clinical features of mild and ordinary disease include fever, dry cough, fatigue, etc, or without prominent symptoms. [6] [7] [8] On the other hand, severe and critical COVID-19 may develop acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, coagulation dysfunction and multi -organ failure, and even death. [9] [10] [11] In China, COVID-19 has been well controlled, with a total of 83537 confirmed cases and 4,634 deaths (July 2, 2020). [12] Compared with the treatment strategies adopted by different countries, it was possible that integration of Chinese medical drugs (CMD) and western medicine (WM) helped the disease control in China. [13] According to the data obtained from the National Administration of Traditional Chinese Medicine, 91.5% of confirmed cases were treated with CMD in China. [14] Study showed CMD could relieve symptoms, prevent disease progression and reduce mortality rate. [15] Core outcome set (COS) refers to an agreed-upon standard set of outcomes that should be measured and reported across different studies. The establishment of a COS helps to unify and compare results obtained from different clinical trials. It can improve the practicability, comparability, and transparency of the results. [16, 17] 

The protocol of this systematic review was registered on PROSPERO (CRD42020176282), and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). [ (2) Received integration of CMD and WM in control group.

(3) Repeated publications, only the first was included. 

The study screening procedures were as follows: (1) Read title and abstract of the manuscripts and eliminated studies based on the inclusion and exclusion criteria. (2) The full text would be examined if additional information was required in the screening process. We designed a standardized data extraction sheet, the extract content included: title, author, study time, sample size, age and gender of J o u r n a l P r e -p r o o f patients, diagnosis, duration of disease, intervention measures, course of treatment and follow-ups, outcomes. When complete information could not be obtained, we contacted the author of the literature by email and excluded the study if failed. Study screening and data extraction were conducted by two researchers independently. Disagreement was resolved after consensus or consultant with the third researcher.

The quality of RCTs were assessed by Cochrane Risk of Bias (ROB) assessment tool, [23] which included six aspects: (1) Random sequence generation, (2) Allocation concealment, (3) Blinding of patients and personnel, (4) Incomplete outcome data, (5) Selective reporting, (6) Other bias. The assessment results were presented as "low risk", "high risk" and "unclear risk". The quality assessment was conducted by two researchers independently. Disagreement was resolved after consensus or consultant with the third researcher.

Review Manager 5.3 was used to do meta-analysis. Dichotomous data were presented as risk ratio (RR), continuous data were calculated as mean difference (MD), clinical symptoms score was calculated as Std mean difference (SMD), and all data was presented with 95% confidence intervals (CIs). Due to the variability between included studies, random effect model was selected to pool the data. The statistical heterogeneity was assessed by P value and I² test. If I²≤50% and P>0.05, the heterogeneity among included studies was considered low. If I²>50% or P≤0.05, the heterogeneity among included studies was considered high. If available data were enough, subgroup analysis or sensitivity analysis would be conducted. The publication bias was evaluated by funnel plot. 

We extracted 2223 articles from 6 databases and excluded 616 due to redundancy. According to the screening criteria, 1526 articles were removed from our list based on their titles and abstracts. 81 articles were downloaded for further assessment, and 70 articles were excluded due to following reasons (1) Not clinical trial (n=23); (2) Not RCTs (n=39); (3) The outcome didn't match the inclusion criteria (n=4); (4) The intervention didn't match the inclusion criteria (n=2); (5) Repeated publications (n=1); (6) Abstract (n=1). As a result, eleven articles were included in this systematic review. The process of study screening was shown in Figure 1 .

The details of study characteristics were summarized in Table 1 . Eleven RCTs [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The quality of included RCTs were generally unclear. Eight studies reported adequate random sequence generation process were defined as low risk. [24, 25, 27, 28, 30, 31, 33, 34] One study reported allocation was concealed from laboratory personnel and outcome assessors, defined as low risk in selection bias and detection bias, high risk in performance bias. [33] One study reported the blinding of patient, defined as low risk in performance bias. [25] Two studies were not blinded due to emergency, defined as high risk in allocation concealment and blinding. [28, 31] Incomplete outcome data had not been found in all studies, the risk of attrition bias were evaluated as low. Other parts of ROB were defined as unclear risk because of insufficient information ( Figure 2 ).

Eight studies (989 patients) reported composite events (number of patients turned to severe and critical type, all-cause death). [25] [26] [27] [28] 30, 31, 33, 34] All of eight studies reported number of patients reported number of all-cause death. [33, 34] [33, 34] No heterogeneity was identified between two studies (I 2 =0%). From the result of meta-analysis, we did not observe significant difference between experimental and control group (RR=0.50, 95% CI=[0.08, 3.00], P= 0.45) ( Figure 3B ).

One study reported the length of hospital stay. [29] [29] It showed that CMD can reduce the length of 

Eight studies (1152 patients) reported the adverse events. [24] [25] [26] [27] [28] [29] 32, 34] Three of them reported no adverse events, [26, 27, 34] and five studies reported the occurrence of adverse events included gastrointestinal reaction (nausea, vomiting, diarrhea, loss of appetite), abnormal liver function, renal dysfunction, headache and pruritus. [24, 25, 28, 29, 32] As shown in Table 1 , gastrointestinal reaction was the main adverse event in both experiment and control groups. The result of meta analysis indicated there was no statistically significant difference between two groups. So CMD may not increase the incidence of adverse events ( Table 2 ).

Since the sample of included study was small, the assessment of publication bias was waived.

The certainty of evidence was generally moderate and low. The results of number of patients turned to the types of severe and critical, and defervescence time were moderate level. The results of length of hospital stay and resolution rate of cough, fatigue and tachypnea were low level. The main reasons of downgrade were unclear risk of bias and small sample size (Table 3) . [36, 38] FiO2/PaO2 ratio and ventilation time were not mentioned in these studies due to limited number of severe and/or critical cases enrolled. However, besides these two, all outcomes in the core outcome set were reported in different studies. It suggested that the core outcome set for COVID-19, i.e. COS-COVID, was well accepted by all related studies. However, it seemed that the outcomes like the number of patients turned to severe and critical type and clinical symptom resolution were more emphasized, especially among studies conducted early in the outbreak.

CMD may decreased the rate of disease progression, shorten the course of treatment, relief symptom and may not increase the incidence of adverse events. Although such results was promising, when referring to these results, the individual differences of patients should be paid attention to, especially the differences of TCM syndromes. And the specificity of COVID-19 across regions also needs to be considered.

There were several limitations of this systematic review. Firstly, we only included published clinical trials with limited sample size. Some trials which were not published were not included. There was potential publication bias. Secondly, most of COVID-19 clinical trials were carried out in real world practice leading to less frequent use of blind methods in the studies, and most of included studies did not report registration process. As a consequence, performance bias during clinical trials were not well controlled. Thirdly, the course of treatment in included studies were no more than 15 days and the follow-up was insufficient, which made the long-term efficacy of CMD for COVID-19 treatment could not be evaluated. Finally, this review evaluated the efficacy and safety of the integration therapy of CMD and WM in the treatment of COVID-19, which contained several different interventions and led to inter-study heterogeneity.

The results of this review are consistent with prior systematic reviews [39] [40] [41] [42] , and substantially updated the evidence of CMD for COVID-19 treatment. Compared with the last published systematic review of RCTs, [42] this review included four new RCTs, [27, [28] [29] [30] and evaluated the efficacy focused J o u r n a l P r e -p r o o f on core outcomes. Compared with other three systematic reviews that included both RCTs and observational studies, [39] [40] [41] this review excluded the observational studies and updated the data of RCTs.

In this review, six kinds of Chinese medical drugs were evaluated, the results of meta-analyses showed CMDs had benefit effects. Thus CMD might be an option for better treatment of COVID-19.

However, due to the limitation of evidence level and quality of included studies, we can not make this recommendation with full confidence.

Rigorous RCTs on CMD for the treatment of COVID-19 are still urgently needed, especially for the severe and critical type. Study investigator should pay more attention to COS-COVID. The course of treatment and follow up should be extended, in order to evaluate the long term efficacy of CMD. The quality of RCTs should be paid attention to, especially for blinding and registration.

In conclusion, the results of meta-analysis suggested that CMD may bring benefit in the treatment of COVID-19 and may not increase the incidence of adverse events. However, the methodological quality of included studies was relatively unclear which might decrease the reliability of the results. Rigorous designed RCTs are still urgently needed. Hu [28] , Li [29] , Xiao [32] , Yu [34] T, Treatment group/Experimental group; C, control group; MD, mean difference; RR, risk ratio;

J o u r n a l P r e -p r o o f

A Novel Coronavirus from Patients with Pneumonia in China

Therapeutic strategies for COVID-19 based on its pathophysiological mechanisms

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV

COVID-19: immunopathology and its implications for therapy

Review and Prospect of Pathological Features of Corona Virus Disease

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

A Review of Coronavirus Disease-2019 (COVID-19)

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Beijing. China: National Health Commission of the People's Republic of China

Central People's Government of the People's Republic of China. The deployment of further classification of effective prevention and control requires the optimization of diagnosis and treatment to speed up the scientific prevention and control of drugs. Beijing. China: Central People's Government of the People's Republic of China

News Conference of the State Council Information Office: Yu Yanhong Briefing the Important Role of TCM in COVID-19 Containment and Treatment. Beijing. China: State Council Information Office

Zhang Boli: traditional Chinese medicine plays a role in the prevention and treatment on novel coronavirus pneumonia

Developing core outcome sets for clinical trials: issues to consider

The COMET handbook: version 1.0

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Trial Version 5. Beijing. China: National Health Commission of the People's Republic of China

National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Trial Version 6. Beijing. China: National Health Commission of the People's Republic of China

National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Trial Version 7. Beijing. China: National Health Commission of the People's Republic of China

Cochrane Handbook for Systematic Review of Interventions

Clinical Effect and Mechanism of Qingfei Touxie Fuzheng Recipe in the Treatment of Novel Coronavirus Pneumonia. Herald of Medicine

Clinical observation on the treatment of novel coronavirus pneumonia with Jinhua qinggan granules

Clinical study on 37 case of COVID-19 treated with integrated traditional Chinese and Western Medicine

Clinical Study on Treatment of Cases of COVID-19 with Toujie Quwen Granules

Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial

Evaluation on the Clinical Effect of Traditional Chinese Medicine and Western Medicine Regimens on COVID-19

Efficacy Observation of Maxing Xuanfei Jiedu Decoction on Common Type of NCP

Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19

The value analysis of traditional Chinese medicine shufeng jiedu capsule combined with abidor in the treatment of mild COVID-19

Guideline-Based Chinese Herbal Medicine Treatment Plus Standard Care for Severe Coronavirus Disease 2019 (G-CHAMPS): Evidence From China

Clinical observation of Lianhua Qingwen Granule combined with

Abidor in the treatment of mild COVID-19

Recent advances in treatment of viral pneumonia using Chinese patent medicine

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Traditional Chinese medicine for COVID-19 treatment

National Administration of Traditional Chinese Medicine. The efficacy of TCM against COVID-19 has been well tested by clinical data. Beijing. China: National Administration of Traditional Chinese Medicine

The Curative Effect on Treating COVID-19 by Integrated Medicine: A systematic Review

Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis

Clinical effects of integrated traditional Chinese and western medicine on COVID-19: a systematic review

Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Chinese medical drug and western medicine compared to western medicine for coronavirus disease 2019 Patient or population: Patients with coronavirus disease 2019 Intervention

The authors declared that there was no conflict of interest regarding the publication of this paper.

This work is supported by the COVID-19 Prevention and Treatment Drug Development Program (2020-CMKYGG-03).

This work did not require an ethics approval as it did not involve any human or animal experiment.

The authors confirm that the data supporting the findings of this study will be made available on request.

GRADE Working Group grades of evidence: High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; MD: Mean difference a. Unclear risk of bias b. Small sample size c. High heterogeneity